Teaching hospital

Neutron Therapeutics' Accelerator Receives Final Acceptance at University of Birmingham's High Flux Accelerator-Driven Neutron Facility

Retrieved on: 
onsdag, december 13, 2023
Science, Biotechnology, Research, Health, Energy, University, Education, Nuclear, Neutron, Outline of physical science, High Flux Isotope Reactor, Therapy, Physics, Head, Glioblastoma, BNCT, Teaching hospital, Radiation, Medicine, Nuclear energy, United, BEI, University of Birmingham, Engineering, Cancer, EPSRC, Environment, Lithium, Medical imaging

Neutron Therapeutics , a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced that its compact accelerator has received final acceptance for use at the University of Birmingham's High Flux Accelerator-Driven Neutron Facility.

Key Points: 
  • Neutron Therapeutics , a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced that its compact accelerator has received final acceptance for use at the University of Birmingham's High Flux Accelerator-Driven Neutron Facility.
  • This first-of-its-kind facility will enable research into the effects of neutrons in a variety of fields, including nuclear energy, nuclear science and boron neutron capture therapy (BNCT).
  • This facility is the United Kingdom’s first high-flux neutron test facility.
  • “The compact accelerator at the University of Birmingham’s neutron facility provides an excellent environment for researchers conducting pre-clinical research in boron neutron capture therapy,” said Professor Stuart Green, director of medical physics at University Hospital Birmingham.

MBrace Therapeutics Presents Preclinical Data Demonstrating Potential of Novel Antibody Drug Conjugate at 2023 San Antonio Breast Cancer Symposium

Retrieved on: 
torsdag, december 7, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, MMAE, MBrace, Safety, Research and development, New Jersey Medical School, Spacecraft, Therapy, Annexin A5, Immunoglobulin G, ADC, HED, Breast cancer, Teaching hospital, Patient, TNBC, Division, Laboratory, Breast, Cancer, Professor, Cell, Cooper University Hospital, HR, Medical imaging

MBrace Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets, today announced new preclinical data supporting ongoing development for lead investigational ADC therapeutic, MBRC-101, at the San Antonio Breast Cancer Symposium taking place December 5-9, 2023, in San Antonio, Texas.

Key Points: 
  • MBrace Therapeutics, Inc. (“MBrace”), a clinical-stage biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets, today announced new preclinical data supporting ongoing development for lead investigational ADC therapeutic, MBRC-101, at the San Antonio Breast Cancer Symposium taking place December 5-9, 2023, in San Antonio, Texas.
  • In the data presented today, robust and selective EphA5 expression was detected in greater than 80% of triple negative breast cancer (TNBC) and greater than 80% of HR+ breast cancer tissue samples.
  • EphA5 expression was not detected in adjacent, non-malignant breast tissue or normal breast.
  • Details of the poster presentation are as follows:
    Presenter: Fernanda Staquicini, Ph.D., Director of Research & Development, MBrace Therapeutics

World Renowned Cancer Researchers From Spain and U.S. Join Forces to Address Critical Needs and Challenges in Women’s Cancer Research

Retrieved on: 
torsdag, december 7, 2023
Research, Entrepreneur, Philanthropy, Oncology, Consumer, Catalog, Cosmetics, Retail, Foundation, Science, Women, Health, Woman, Organization, Incidence, Breast cancer, Chair, Hospital, Teaching hospital, Patient, Multimedia, Skin care, Prognosis, Cancer, Courtesy, Baylor University Medical Center, Frustration, TNBC, Pharmaceutical industry, Dietary supplement, Medical device

Both lead their own research teams in their respective home countries focused on investigating the rare and aggressive form of cancer in women: triple negative metastatic breast cancer (TNBC).

Key Points: 
  • Both lead their own research teams in their respective home countries focused on investigating the rare and aggressive form of cancer in women: triple negative metastatic breast cancer (TNBC).
  • Dr. O'Shaughnessy added, “In 1985, we were terribly frustrated by the lack of therapeutic options for women with cancer.
  • Mary Kay is at the forefront of women's cancer research, supporting groundbreaking research led by women for women.
  • Mary Kay is committed to helping researchers around the world by supporting translational research (research that links laboratory research directly to the patient), clinical trials aimed at improving the detection, prognosis, and treatment of women's cancers, as well as organizations that support cancer research, such as the FERO Foundation in Spain.

Alentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Retrieved on: 
torsdag, november 16, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, USC, Assistant, Associate, Safety, Vall, Head, Clinical research, Teaching hospital, Multimedia, CLDN1, Pharmacokinetics, Neoplasm, University, Cancer, University of Southern California, Pharmaceutical industry, Medicine, MD

The patient is enrolled under the Phase I program, led by Anthony El-Khoueiry, MD, Associate Director of Clinical Research, at University of Southern California (USC) Norris Comprehensive Cancer Center, part of Keck Medicine of USC.

Key Points: 
  • The patient is enrolled under the Phase I program, led by Anthony El-Khoueiry, MD, Associate Director of Clinical Research, at University of Southern California (USC) Norris Comprehensive Cancer Center, part of Keck Medicine of USC.
  • View the full release here: https://www.businesswire.com/news/home/20231116577905/en/
    The open-label, multi-center, Phase 1/2 clinical trial ( NCT06054477 ) will investigate ALE.C04 as a single agent and in combination with pembrolizumab (anti-PD-1 antibody) in 220 adults with recurrent or metastatic (R/M) head and neck squamous cell carcinoma.
  • “ALE.C04 is a first-in-class antibody for treating cancer and has shown much potential in preclinical models,” said Luigi Manenti, MD, Chief Medical Officer of Alentis.
  • I am looking forward to the data and to developing ALE.C04 for other CLDN1+ tumors including colorectal cancer.”

Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis

Retrieved on: 
fredag, november 17, 2023
Health, Other Health, Other Science, General Health, Science, Pharmaceutical, Biotechnology, Allergic conjunctivitis, Itch, Adolescence, ALM, Adherence, Safety, Hope, European Commission, Advocate, Disease, Teaching hospital, Civil service commission, TCS, Patient, Week, Doctor of Philosophy, Conjunctivitis, Atopic dermatitis, BME, Eli Lilly and Company, MD, Skin, Almirall, Human, Pharmaceutical industry, Vaccine, Dermatology

“The arrival of novel biologic treatments is marking a new paradigm in the management of atopic dermatitis.

Key Points: 
  • “The arrival of novel biologic treatments is marking a new paradigm in the management of atopic dermatitis.
  • The approval of lebrikizumab represents a leap forward in our ability to provide patients with an effective therapeutic option with demonstrated safety profile.
  • Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including atopic dermatitis, in Europe.
  • Almirall expects regulatory decisions for lebrikizumab in moderate-to-severe atopic dermatitis in additional European markets, including the United Kingdom and Switzerland.

Northwell Receives Largest Single Gift in Its History From Victoria and Lloyd Goldman to Support Expansion in Manhattan

Retrieved on: 
onsdag, november 15, 2023
Commercial Building & Real Estate, Construction & Property, Hospitals, Cardiology, Philanthropy, Practice Management, Managed Care, Health, Other Philanthropy, Constellation, Lloyd Goldman, Woman, Research, Metropolitan, Surgical oncology, DSM-IV codes, Radiation, Teaching hospital, Metropolitan Museum of Art, Lenox Health Greenwich Village, Multimedia, Oncology, Triple-negative breast cancer, Pharmacy, Heart, North Shore University Hospital, Third Avenue, Endometrial cancer, Weekend Update, Medical research, Lenox Hill Hospital, Hospital, Cancer, Imaging, Impossible, Medical imaging, Pharmaceutical industry, Management, New Yorker, Northwell Health, Art

In gratitude for a significant gift from Victoria and Lloyd Goldman — the largest single gift in Northwell’s history — Northwell Health will name its new medical pavilion under construction on the Upper East Side of Manhattan the Victoria and Lloyd Goldman Medical Pavilion.

Key Points: 
  • In gratitude for a significant gift from Victoria and Lloyd Goldman — the largest single gift in Northwell’s history — Northwell Health will name its new medical pavilion under construction on the Upper East Side of Manhattan the Victoria and Lloyd Goldman Medical Pavilion.
  • The gift was announced at Northwell’s annual Constellation Gala held at the Metropolitan Museum of Art on November 14th and includes an endowment to establish the Victoria and Lloyd Goldman Professorship.
  • View the full release here: https://www.businesswire.com/news/home/20231115848930/en/
    L-r: Northwell President and CEO Michael J. Dowling and benefactors Lloyd and Victoria Goldman stand beside a model of the future Victoria and Lloyd Goldman Medical Pavilion, which is slated to open on the Upper East Side of Manhattan in 2026.
  • The undisclosed gift amount contributes toward the $450 million, 15-floor, 200,000-square-foot complex, which is slated to open in 2026.

University of Basel Delivers First Biological Implants for Treatment of Cartilage Lesions and Osteoarthritis in Humans

Retrieved on: 
onsdag, november 15, 2023
Research, Surgery, FDA, Clinical Trials, Stem Cells, Other Health, Biotechnology, Physical Therapy, Health, Science, Spotify, N, Sport, Knee, Teaching hospital, Life, Ankle, Patient, Rheumatoid arthritis, Knee pain, Arthritis, Ice, Nasal septum, University Children's Hospital Basel, Torture, Doctor of Philosophy, Skiing, Quality of life, Government, Inflammation, Crutch, Swiss National Science Foundation, Surgeon, Tissue engineering, Cartilage, Regenerative medicine, European, University Hospital of Basel, Arthralgia, University of Basel, Chondrocyte, Animal, OA, University, Elbow, Apple, Walking, Cell, Motion, Brain, Hope, Joint, PFOA, MD, Human, Swimming, Leg, Dentistry, Pharmaceutical industry, Osteoarthritis

The Department of Biomedicine at the University of Basel and the University Hospital Basel, today announced that it delivered the first surgical procedure to treat Osteoarthritis (OA) in humans.

Key Points: 
  • The Department of Biomedicine at the University of Basel and the University Hospital Basel, today announced that it delivered the first surgical procedure to treat Osteoarthritis (OA) in humans.
  • Chondrocytes are the cell building blocks for cartilage and the University of Basel team is using them to grow new cartilage.
  • Expanding beyond focal lesions six years ago, the University of Basel team treated two patients with advanced knee OA – patients who had been scheduled for knee joint replacement.
  • The team at the University of Basel are providing folks like us with new hope.

Thomas Jefferson University Names Said Ibrahim, MD, MBA, MPH the Anthony F. and Gertrude M. DePalma Dean of Sidney Kimmel Medical College

Retrieved on: 
torsdag, december 14, 2023
Health equity, Interim, National academy, Teaching hospital, Patient, MBA, School of Public Health, Medical college, Doctor of Philosophy, Bangladesh Technical Education Board, School, Internal medicine, JUP, Thomas Jefferson University, Division, North Shore University Hospital, Northwell Health, Health, Harvard Medical School, Knee, Public health, Innovation, Physician, Harvard University, Weill Cornell Medicine, Student, Mentorship, University, Diversity, Master, Education, Jefferson Health, Research, Bachelor, National Academy of Medicine, Faculty, Inclusion, Business administration, NIH, MD, MPH, Brigham and Women's Hospital, Hospital, Nursing, Medicine, Veteran

PHILADELPHIA, Dec. 14, 2023 /PRNewswire/ -- On December 1, Jefferson welcomed newly appointed Anthony F. and Gertrude M. DePalma Dean of Thomas Jefferson University's esteemed Sidney Kimmel Medical College and president of Jefferson University Physicians (JUP), Said Ibrahim, MD, MBA, MPH. Dr. Ibrahim is an internal medicine physician who has served as a primary care doctor, educator, administrator, and clinician investigator, brings a wealth of higher education, research and healthcare experience to this crucial leadership role, and is nationally recognized for his efforts to combat health disparities.

Key Points: 
  • PHILADELPHIA, Dec. 14, 2023 /PRNewswire/ -- On December 1, Jefferson welcomed newly appointed Anthony F. and Gertrude M. DePalma Dean of Thomas Jefferson University's esteemed Sidney Kimmel Medical College and president of Jefferson University Physicians (JUP), Said Ibrahim, MD, MBA, MPH.
  • "Dr. Ibrahim has demonstrated a strong commitment to fostering innovation, collaboration and inclusivity within the medical community," said Susan Aldridge, PhD, Interim President of Thomas Jefferson University.
  • As Dean, Dr. Ibrahim will build upon the existing collaborative, transdisciplinary, and vibrant culture to further position the Sidney Kimmel Medical College and Jefferson Health as a premier academic healthcare institution in Philadelphia and beyond.
  • Dr. Ibrahim received his Bachelor's degree from Oberlin College and his Medical degree from Case Western Reserve University School of Medicine.

IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate

Retrieved on: 
tisdag, november 28, 2023
Safety, Treatment, Patient safety, Freezing, Teaching hospital, Patient, University of Montpellier, Neoplasm, Success, University, Kidney, MES, Urology, Physician, Quality of life, Curie Institute, Medical imaging, Pharmaceutical industry, Cancer, Study

ProSense® is approved for the treatment of benign and malignant kidney tumors in the U.S., Europe, and numerous other countries.

Key Points: 
  • ProSense® is approved for the treatment of benign and malignant kidney tumors in the U.S., Europe, and numerous other countries.
  • The causes of partial tumor response and persistent tumor residue after a T1a renal cryoablation procedure were assessed.
  • "The authors' findings are similar to the interim results from our own ICESECRET study in small renal masses which demonstrated an 89.5% recurrence-free rate.
  • We expect ICESECRET's five-year patient follow-up to be completed in 2026, with topline results available shortly afterwards."

Fresh Start Surgical Gifts Teams Up with Get Maine Lobster For an Unforgettable Giving Tuesday and Beyond

Retrieved on: 
tisdag, november 21, 2023
Sale, Comer Children's Hospital, SAN, Hope, Hospital Metropolitano de Santiago, Rady Children's Hospital, Fresh Start, Teaching hospital, Patient, Child, Partnership, Health, Family, Taste, Hospital, Lobster

On Giving Tuesday and beyond, Get Maine Lobster will be giving back to Fresh Start by donating 5 percent of sales.

Key Points: 
  • On Giving Tuesday and beyond, Get Maine Lobster will be giving back to Fresh Start by donating 5 percent of sales.
  • On Giving Tuesday and beyond, Get Maine Lobster will be giving back to Fresh Start by donating five percent of sales on their website.
  • "Teaming up with Get Maine Lobster is such an amazing opportunity for us," says Shari Brasher, the CEO of Fresh Start Surgical Gifts.
  • Join Fresh Start Surgical Gifts and Get Maine Lobster on Giving Tuesday, November 28, for a unique opportunity to savor fresh lobster and provide children with the fresh start they deserve.